



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Águeda Molinos-Quintana
✉ agueda.molinos.sspa@juntadeandalucia.es;
✉ aguedamolinos@hotmail.com
Anna Alonso-Saladrígues
✉ anna.alonso@sjd.es

RECEIVED 20 January 2024
ACCEPTED 25 January 2024
PUBLISHED 07 February 2024

CITATION

Molinos-Quintana Á, Alonso-Saladrígues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torredadell M, Delgado-Serrano J, Pérez de Soto C, Faura A, González-Martínez B, Castillo-Robleda A, Díaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives S and Pérez-Simón JA (2024) Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring. *Front. Immunol.* 15:1373852. doi: 10.3389/fimmu.2024.1373852

COPYRIGHT

© 2024 Molinos-Quintana, Alonso-Saladrígues, Herrero, Caballero-Velázquez, Galán-Gómez, Panesso, Torredadell, Delgado-Serrano, Pérez de Soto, Faura, González-Martínez, Castillo-Robleda, Díaz-de-Heredia, Pérez-Martínez, Pérez-Hurtado, Rives and Pérez-Simón. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

Águeda Molinos-Quintana^{1*}, Anna Alonso-Saladrígues^{2*}, Blanca Herrero³, Teresa Caballero-Velázquez⁴, Víctor Galán-Gómez⁵, Melissa Panesso⁶, Montserrat Torredadell², Javier Delgado-Serrano⁴, Concepción Pérez de Soto¹, Anna Faura², Berta González-Martínez⁵, Ana Castillo-Robleda³, Cristina Díaz-de-Heredia⁶, Antonio Pérez-Martínez⁵, José María Pérez-Hurtado¹, Susana Rives^{7,8} and José Antonio Pérez-Simón⁴ on behalf of Spanish Group for Bone Marrow Transplantation and Cellular therapy group (GETH-TC)

¹Pediatric Unit, Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain, ²CAR T-cell Unit. Leukemia and Lymphoma Department. Pediatric Cancer Center Barcelona (PCCB). Hospital Sant Joan de Déu de Barcelona, Barcelona, Spain, ³Pediatric Hemato-Oncology Department, Pediatric University Hospital del Niño Jesús, Madrid, Spain, ⁴Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain, ⁵Pediatric Hemato-Oncology Department, University Hospital La Paz, Institute for Health Research (IdiPAZ), Universidad Autónoma de Madrid, Madrid, Spain, ⁶Division of Pediatric Hematology and Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain, ⁷Pediatric Cancer Center Barcelona (PCCB), Institut de Recerca Sant Joan de Déu, Leukemia and Pediatric Hematology Disorders, Developmental Tumors Biology Group, Barcelona, Spain, ⁸Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red De Enfermedades Raras (CIBERER), Madrid, Spain

KEYWORDS

B cell aplasia, late B-cell recovery, pre-infusion tumor burden, CD19 CART-cells, relapsed/refractory acute lymphoblastic leukemia, tisagenlecleucel, B-cell monitoring

A Corrigendum on

Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

by Molinos-Quintana Á, Alonso-Saladríguez A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torrebadell M, Delgado-Serrano J, Pérez de Soto C, Faura A, González-Martínez B, Castillo-Robleda A, Díaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives S and Pérez-Simón JA (2024) *Front. Immunol.* 14:1280580. doi: 10.3389/fimmu.2023.1280580

In the published article, there was an error in the author list, and author “on behalf of **Spanish Group for Bone Marrow Transplantation and Cellular therapy group (GETH-TC)**” was erroneously excluded. The corrected author list appears below.

Águeda Molinos-Quintana^{1*}, Anna Alonso-Saladríguez^{2*}, Blanca Herrero³, Teresa Caballero-Velázquez⁴, Víctor Galán-Gómez⁵, Melissa Panesso⁶, Montserrat Torrebadell², Javier Delgado-Serrano⁴, Concepción Pérez de Soto¹, Anna Faura², Berta González-Martínez⁵, Ana Castillo-Robleda³, Cristina Díaz-de-Heredia⁶, Antonio Pérez-Martínez⁵, José María Pérez-Hurtado¹, Susana Rives^{7,8}, José Antonio Pérez-Simón⁴ on behalf of Spanish Group for Bone Marrow Transplantation and Cellular therapy group (GETH-TC)

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.